Siemens Healthineers Halts General Ultrasound Sales to Focus on Cardiovascular Procedures

Key points

• Sales of general imaging ultrasound systems, including the Acuson Sequoia, Redwood, Juniper, and Maple, have ended as of October 12, 2026.
• The company is shifting its ultrasound division to focus exclusively on procedural imaging, image-guided therapies, and cardiovascular disease management.
• Remaining products include the Acuson Origin, P500, and Freestyle systems, which feature AI capabilities and FDA clearance for cardiovascular use.
• Siemens Healthineers will provide maintenance, software updates, and service for all existing general imaging systems throughout their lifecycle.
• The ultrasound division generated over €600 million in revenue in 2025, representing 9% of the Precision Therapy division's total revenue.

Background

This strategic pivot follows earlier announcements in 2026 regarding Siemens Healthineers' expansion into other medical technologies, such as the Accela radiotherapy platform launched in September. The company had previously considered selling its ultrasound division but abandoned those plans; this latest move represents a final decision to exit the general imaging market rather than divest the entire unit.

How outlets are covering it

Cardiovascular Business emphasizes the strategic focus on intracardiac echocardiography and AI, quoting Sourabh Pagaria, head of ultrasound, who stated that imaging is increasingly becoming part of therapy. Reuters, via MarketScreener, highlights the competitive disadvantage Siemens Healthineers faced against larger providers like Philips, GE Healthcare, Fujifilm, and Canon, noting that the company could not hold its own in the general imaging market. VZ VermögensZentrum confirms the shift to procedural imaging and image-guided therapy, noting that the company will continue to sell catheters and software to electrophysiologists. All sources agree that existing customers will be supported, but Reuters specifically notes that the market for general ultrasound is well-served by other established providers, mitigating patient care risks.

Why it matters

This decision signals a significant consolidation in the medical imaging market, as Siemens Healthineers retreats from a segment where it lacks competitive scale. By focusing on high-margin, specialized cardiovascular procedures, the company aims to improve profitability and leverage its AI and software strengths. For the broader healthcare industry, this move may intensify competition among remaining general ultrasound providers and accelerate the adoption of AI-driven procedural imaging in cardiology.

What to watch

Siemens Healthineers will continue to support existing customers with general imaging systems through maintenance and software updates. The company will focus on expanding its cardiovascular ultrasound portfolio, including the Acuson Origin, and deepen partnerships with cardiovascular device companies. Analysts will monitor the financial impact of this shift, particularly given that the ultrasound division contributed 9% to the Precision Therapy division's revenue in 2025.